Rovi Pharmaceutical Laboratories He communicates that, Rois Phoenix Inc. (the buyer), a filial entirely participated by Rovi Pharma Industrial Services, Sau, has signed a sale contract (Asset Purchase Agreement) With Bristol Myers Squibb (BMS) for the acquisition of a drug manufacturing plant located in Phoenix, Arizona (USA) (the plant) along with a series of assets and liabilities related to it (the operation).
Within the framework of the operation, the buyer has signed with BMS a toll manufacturing Agreement, which regulates the conditions under which the buyer will continue to manufacture for BMS in the plant. The agreement has an initial duration of five years from the closing of the operation and includes a minimum payment of 50 million dollars for each year of contract.
With this operation, Rovi expands the Rois manufacturing network with the incorporation of a new state -of -the -art plant, which increases the production capacity of injectables, reinforces alliances and supports the supply of medicines. William Blair has acted as an exclusive financial advisor of Bristol Myers Squibb.
The acquisition of the plant, which will close for a non -significant amount for Roviis subject to compliance with certain usual suspensive conditions in this type of operations. The closure of the operation is scheduled for the first semester of 2026.
